Sensorion SA (ALSEN)

Currency in EUR
0.4015
+0.0140(+3.61%)
Closed·
ALSEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.38400.4025
52 wk Range
0.27300.8080
Key Statistics
Prev. Close
0.4015
Open
0.39
Day's Range
0.384-0.4025
52 wk Range
0.273-0.808
Volume
896.47K
Average Volume (3m)
3.43M
1-Year Change
-17.2165%
Book Value / Share
0.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALSEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.3025
Upside
+224.41%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Sensorion SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.3025
(+224.41% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy1.10+173.97%1.50Maintain10/03/2026

Earnings

Latest Release
18/03/2026
EPS / Forecast
-0.04 / -0.05
Revenue / Forecast
3.5M / 2.3M
EPS Revisions
Last 90 days

Compare ALSEN to Peers and Sector

Metrics to compare
ALSEN
Peers
Sector
Relationship
P/E Ratio
−7.0x−2.8x−0.5x
PEG Ratio
0.99−0.040.00
Price/Book
4.6x−0.7x2.6x
Price / LTM Sales
35.5x14.2x3.2x
Upside (Analyst Target)
175.2%184.9%47.8%
Fair Value Upside
Unlock0.7%5.9%Unlock

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
37.79M7.34%14.64M
Other Institutional Investors
221.15M42.97%85.70M
Public Companies & Retail Investors
255.78M49.69%99.12M
Total
514.72M100.00%199.45M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Artal International SCA15.73%80,980,54731,380
Redmile Group, LLC12.83%66,052,59025,595

People Also Watch

5.010
MEMS
+6.48%
3.4100
ABNX
0.00%
50.05
ALSTI
+9.47%
1.20
ALWTR
+0.84%
0.0140
ALTAO
-9.09%

FAQ

What Is the Sensorion SA (Paris: ALSEN) Share Price Today?

The Sensorion SA stock price today is 0.4015 EUR.

What Stock Exchange Does Sensorion SA (ALSEN) Trade On?

Sensorion SA is listed and trades on the Paris Stock Exchange.

What Is the Ticker (Stock Symbol) for Sensorion SA?

The stock symbol (also called a 'ticker') for Sensorion SA is "ALSEN."

What Is the Current Sensorion SA Market Capitalisation?

As of today, Sensorion SA (Paris: ALSEN) market cap is 206.6600M EUR.

What Is Sensorion SA's (ALSEN) Earnings Per Share (TTM)?

The Sensorion SA EPS is currently -0.0980 (Trailing Twelve Months).

When Is the Next Sensorion SA Earnings Date?

Sensorion SA's next earnings report will be released on 03/06/2026.

Is ALSEN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Sensorion SA moving averages and other technical indicators, the daily buy/sell signal for ALSEN stock is Strong Buy.

How Many Times Has Sensorion SA Stock Split?

Sensorion SA has split 0 times. (See the ALSEN stock split history page for full effective split date and price information.)

How Many Employees Does Sensorion SA Have?

Sensorion SA has 63 employees, based on their latest Companies House report.

What is the current trading status of Sensorion SA (Paris: ALSEN)?

As of 06/05/2026, Sensorion SA (ALSEN) is trading at a share price of 0.4015 EUR, with a previous close of 0.4015 EUR. The stock has fluctuated within a day range of 0.3840 EUR to 0.4025 EUR, while its 52-week range spans from 0.2730 EUR to 0.8080 EUR.

What Is Sensorion SA (ALSEN) Price Target According to Analysts?

The average 12-month price target for Sensorion SA is 1.3025 EUR, with a high estimate of 2 EUR and a low estimate of 1 EUR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +224.41% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.